Related Experiment Video
Updated: Feb 27, 2026
07:42
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.9K
A Perplexing Plexopathy After Pembrolizumab Therapy in Early-Stage Triple-Negative Breast Cancer
Toluwalogo Baiyewun1, Brian McNamara2, Emily Aherne3
1University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland.
Current Oncology (Toronto, Ont.)
|February 26, 2026
Summary
This case highlights a rare immune-related neuropathy in a triple-negative breast cancer patient treated with immunotherapy. Plasmapheresis effectively treated this condition, emphasizing the need for personalized strategies balancing cure with survival quality.
Area of Science:
- Oncology
- Immunology
- Neurology
Background:
- Triple-negative breast cancer (TNBC) treatment benefits from immunotherapy, but immune-related adverse events (irAEs) can be complex, especially in patients with autoimmune conditions.
- Standardized treatment protocols may not adequately address unique toxicities or optimize response-adapted strategies for patients with pre-existing autoimmune issues.
- Recognizing immunotherapy-induced toxicity distinct from cancer recurrence is crucial for managing long-term survival and quality of life.
Keywords:
EMGautoimmune neuropathiesimmune-related adverse eventsimmunotherapynerve injuryplasmapheresistriple-negative breast cancerMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K